Intravenous iron in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Hematology
• Internal Medicine

Background:

• Anemia is prevalent in inflammatory bowel disease (IBD) patients, affecting up to 30%.
• Iron deficiency (ID) is a major contributor, with a prevalence of 45% in IBD.
• Both anemia and ID significantly impair patient quality of life.

Purpose of the Study:

• To review the management of anemia and iron deficiency in IBD patients.
• To highlight the benefits of timely iron replacement therapy.
• To discuss the role and types of intravenous (i.v.) iron formulations.

Main Methods:

• Literature review of studies on anemia and iron deficiency in IBD.
• Analysis of the efficacy and safety of oral versus i.v. iron.
• Comparison of different i.v. iron products and their indications.

Main Results:

• Intravenous iron offers faster hemoglobin increase and iron store repletion compared to oral iron.
• Specific patient groups benefit from i.v. iron, including those with severe anemia or intolerance to oral iron.
• Newer i.v. iron preparations allow for higher single doses, simplifying treatment and improving outcomes.

Conclusions:

• Early detection and treatment of anemia and ID are crucial for IBD patients.
• Intravenous iron is a safe and effective option, particularly in specific clinical scenarios.
• Effective anemia management improves quality of life and avoids blood transfusions in IBD.